Skip To Main Content
Rutie Yin on Muck Rack

Rutie Yin

As seen in: Nature, Frontiers, Frontiers in Immunology, JAMA Oncology, Molecular Cancer, EClinicalMedicine, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rutie

Contact Rutie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Global research trends and hotspots in human immunodeficiency virus-associated cervical cancer (1990–2025): a multi-database bibliometric analysis

|
By Lin Sui, Rutie Yin
| Frontiers in Immunology
Abstract Background: Research on cervical cancer among WLWH represents a critical area for advancing long-term prevention and clinical management strategies. Yet as the volume of published literature in this field continues to grow rapidly, synthesizing and appraising the available evidence in a comprehensive manner has become increasingly challenging.
Open in Who Shared Issue with article?

Cervical cancer with BRCA1 gene mutations: case reports and literature review

|
By Jian Yang, Rutie Yin, Lan Zhong
| Frontiers
Abstract Background: Mutations in breast cancer susceptibility genes (BRCA1 and BRCA2) are well-established risk factors for breast, ovarian, prostate, and pancreatic cancers. However, their occurrence in cervical cancer is rare, with a reported prevalence of less than 5%. To date, only a limited number of cervical cancer cases harboring BRCA mutations have been reported. Case presentation: We conducted a retrospective analysis of two cases of cervical cancer with germline BRCA1 mutations.
Open in Who Shared Issue with article?

Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study | Molecular Cancer | Full Text

|
By Jin Billy Li, Jihong Liu, Rutie Yin, Dongling Zou, Hong Zheng, Junning Cao, Zhendong Chen, Wei Sun, Yunong Gao, Songling Zhang, Linjuan Zeng, Ruifang An, Xianping Lu, Shuang Ye, Xiaohua Wu
| Molecular Cancer Verified
From Jul 03, 2019, to Dec 21, 2020, a total of 46 patients were enrolled to receive chiauranib combination therapy (CE group: 24 patients; CP group: 22patients). In the pioneer phase Ib trial, 25 patients were enrolled to receive the monotherapy. In the monotherapy stage, the median patient age was 50 years (34 to 69 years), and 88% of patients had received three or more previous systemic therapies, with none classified as platinum-refractory ovarian cancer patients.
Open in Who Shared Issue with article?
See all 6 articles